MinorAntifungal, triazole×Antiepileptics (other)
Updated · Methodology
Mechanism
The liver metabolises very little levetiracetam. Its main metabolic pathway, hydrolysis of 24% of the dose, does not involve cytochrome P450 enzymes. About 95% of the dose is excreted in the urine (levetiracetam SmPC, European Medicines Agency, EMA). Itraconazole is a strong inhibitor of CYP3A4 and of the transporters P-glycoprotein and BCRP. Through these pathways it changes the levels of other drugs (Sporanox label, US Food and Drug Administration, FDA). Levetiracetam does not inhibit the main cytochrome P450 enzymes. Its weak CYP3A4 induction in liver cells was not significant in the body, so drug interactions are very unlikely (levetiracetam SmPC, EMA). Levetiracetam is not named in the itraconazole interaction tables: the only antiepileptics listed there are carbamazepine, phenobarbital and phenytoin (itraconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and Sporanox label, FDA).
Symptoms
The documents describe no symptoms linked to this combination. Each drug keeps its own adverse effects: for levetiracetam these are somnolence, fatigue, coordination difficulties and changes in behaviour and mood (Keppra label, US Food and Drug Administration, FDA). Rare cases of QT prolongation on the electrocardiogram (ECG) have been reported with levetiracetam after marketing (levetiracetam SmPC, European Medicines Agency, EMA).
Management
According to the documents, the combination is acceptable, and the doses of levetiracetam and itraconazole need no change. No document names the pair, and levetiracetam does not depend on CYP3A4, the enzyme through which itraconazole changes the levels of other drugs (levetiracetam SmPC, European Medicines Agency, EMA; itraconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The only antiepileptics not recommended with itraconazole are carbamazepine, phenobarbital and phenytoin (itraconazole SmPC, AEMPS; Sporanox label, US Food and Drug Administration, FDA). The levetiracetam SmPC advises caution with drugs that affect the QTc interval. The itraconazole documents do not describe QT prolongation by itraconazole itself, only by raised levels of drugs that CYP3A4 metabolises. Levetiracetam is not one of these drugs (levetiracetam SmPC, EMA; itraconazole SmPC, AEMPS). Monitoring levetiracetam blood levels is not required (levetiracetam SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Sporanox 100 mg cápsulas (itraconazol) (2026)– AEMPS CIMA, Sporanox 100 mg cápsulas, nº registro 59343, secciones 4.3 y 4.5
- FDA: Sporanox (itraconazole) capsules prescribing information (2026)– Janssen Pharmaceuticals. SPORANOX (itraconazole) capsules. Prescribing information, DailyMed setid a4d555fa-787c-40fb-bb7d-b0d4f7318fd0, Contraindications and Drug Interactions table
- EMA: Ficha técnica: Levetiracetam (EU/1/00/146), sección 4.5 (2026)– EMA, Keppra 500 mg comprimidos recubiertos con película (UCB Pharma, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 00146010, consultada 29.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5 y 5.2
- FDA: Keppra (levetiracetam) prescribing information (2026)– FDA, DailyMed, UCB, Inc., setid 3ca9df05-a506-4ec8-a4fe-320f1219ab21, v36, 01/2026, sections 5 and 12.3